Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase IB/II Study of Onvansertib PCM-075 in Combination with Either Low-Dose Cytarabine or Decitabine in Subjects with Acute Myeloid Leukemia AML
Chronic Health Conditions in Down Syndrome-Associated Acute Leukemia: The Down Syndrome Phenotyping Acute Leukemia Study in Survivors DS-PALS Survivors
Study Type: Other
Phase: N/A
NCTID: NCT05702645
Principal Investigator:
Keith August
A Phase II, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib INCB050465.
A Multicenter, Open-Label, Phase I Study of AJ1-11095 Administered as Oral Monotherapy in Patients with Primary Myelofibrosis PMF, Post-Polycythemia Vera Myelofibrosis PPV-MF, or Post-Essential Thrombocythemia Myelofibrosis PET-MF Who Have Been Failed by a Type I JAK2 Inhibitor JAK2i
Study Type: Treatment
Phase: I
NCTID: NCT06343805
Principal Investigator:
Abdulraheem Yacoub
A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia
Study Type: Treatment
Phase: I/II
NCTID: NCT04258943
Principal Investigator:
Keith August
A Phase Ib/II Open-Label Study of APVO436 in Combination with Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia AML
Study Type: Treatment
Phase: I/II
NCTID: NCT06634394
Principal Investigator:
Tara Lin
The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Study Type: Other
Phase: N/A
NCTID: NCT02402244
Principal Investigator:
Keith August
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
Study Type: Treatment
Phase: III
NCTID: NCT03007147
Principal Investigator:
Keith August
An Open Label, Single-Center, Pilot Trial of the Combination of Tagraxofusp TAG with Pacritinib PAC in Patients with Intermediate-1 or Higher Myelofibrosis MF, Who Have had Prior Therapy with the Approved JAK1/2 Inhibitors or in Which Therapy with the Approved JAK1/2 Inhibitors is Not Appropriate, Contraindicated or Declined by the Subjects
Study Type: Treatment
Phase: Feasibility/Pilot
NCTID: NCT06414681
Principal Investigator:
Abdulraheem Yacoub
A Phase 3 Trial Investigating Blinatumomab NSC 765986 in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia B-ALL and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma B-LLy
Study Type: Treatment
Phase: III
NCTID: NCT03914625
Principal Investigator:
Keith August